Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–1157.

Article  CAS  PubMed  Google Scholar 

Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272–1284.

Article  CAS  PubMed  Google Scholar 

Singh V, De A, Mehtani R, Angeli P, Maiwall R, Satapathy S et al. Asia-Pacific association for study of liver guidelines on management of ascites in liver disease. Hepatol Int. 2023;17:792–826.

Article  PubMed  Google Scholar 

Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70:9–29.

Article  PubMed  Google Scholar 

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 69:406–60.

Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1014–1048.

Article  PubMed  Google Scholar 

Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019;79:1135–1146.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation. 2020;141:90–99.

Article  CAS  PubMed  Google Scholar 

Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020; 18:2168–72 e2.

Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. J Clin Med. 2023;12:2253.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montalvo-Gordon I, Chi-Cervera LA, García-Tsao G. Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology. 2020;72:1880–1882.

Article  CAS  PubMed  Google Scholar 

Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor. Clin Kidney J. 2022;15:831–833.

Article  CAS  PubMed  Google Scholar 

Kalambokis GN, Tsiakas I, Filippas-Ntekuan S, Christaki M, Despotis G, Milionis H. Empagliflozin Eliminates Refractory Ascites and Hepatic Hydrothorax in a Patient With Primary Biliary Cirrhosis. The American journal of gastroenterology. 2021;116:618–619.

Article  CAS  PubMed  Google Scholar 

Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725–749.

Article  PubMed  Google Scholar 

Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Journal of hepatology. 2012;56:348–354.

Article  CAS  PubMed  Google Scholar 

Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2018;11:141–144.

Article  PubMed  PubMed Central  Google Scholar 

Li HL, Tse YK, Chandramouli C, Hon NW, Cheung CL, Lam LY et al. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. J Clin Endocrinol Metab. 2022;107:3442–3451.

Article  PubMed  PubMed Central  Google Scholar 

Ekpanyapong S, Reddy KR. Infections in Cirrhosis. Curr Treat Options Gastroenterol. 2019;17:254–270.

Article  PubMed  PubMed Central  Google Scholar 

Bajaj JS, Kamath PS, Reddy KR. The Evolving Challenge of Infections in Cirrhosis. The New England journal of medicine. 2021;384:2317–2330.

Article  CAS  PubMed  Google Scholar 

Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology. 2019;156:1368–80.e10.

Article  PubMed  Google Scholar 

Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S et al. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr. 2020;12:37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479–487.

Article  CAS  PubMed  Google Scholar 

Tang L, Wu Y, Tian M, Sjöström CD, Johansson U, Peng XR et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313:E563–E576.

Article  PubMed  Google Scholar 

Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS et al. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obes Metab. 2021;23:2402–2408.

Article  CAS  PubMed  PubMed Central  Google Scholar